MX2022010782A - Sistema de perfusion. - Google Patents

Sistema de perfusion.

Info

Publication number
MX2022010782A
MX2022010782A MX2022010782A MX2022010782A MX2022010782A MX 2022010782 A MX2022010782 A MX 2022010782A MX 2022010782 A MX2022010782 A MX 2022010782A MX 2022010782 A MX2022010782 A MX 2022010782A MX 2022010782 A MX2022010782 A MX 2022010782A
Authority
MX
Mexico
Prior art keywords
patient
container
antineoplastic drug
solution
perfusion
Prior art date
Application number
MX2022010782A
Other languages
English (en)
Inventor
Subhas Balaram Bhowmick
Prashant Kane
Samarth Kumar
Kirti Ganorkar
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MX2022010782A publication Critical patent/MX2022010782A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A61J1/12—Bag-type containers with means for holding samples of contents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/1407—Infusion of two or more substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/16804—Flow controllers
    • A61M5/16827—Flow controllers controlling delivery of multiple fluids, e.g. sequencing, mixing or via separate flow-paths
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/60—General characteristics of the apparatus with identification means
    • A61M2205/6009—General characteristics of the apparatus with identification means for matching patient with his treatment, e.g. to improve transfusion security

Abstract

Un contenedor de perfusión para administrar directamente a pacientes una dosis de un fármaco antineoplásico calculada de acuerdo con un parámetro de paciente, en donde el primer contenedor de perfusión comprende una solución de fármaco antineoplásico a una concentración y volumen tal que la cantidad de fármaco antineoplásico en el contenedor es igual que la dosis calculada para un paciente pero menos que la dosis calculada para un segundo paciente, la dosis calculada es proporcionada al primer paciente dentro de una variación de 5% al administrar directamente el volumen completo de la solución de fármaco antineoplásico desde el primer contenedor de perfusión, además el primer contenedor de perfusión está acompañado por un segundo contenedor de perfusión complementario que comprende una solución de fármaco antineoplásico a una concentración y volumen tal que la dosis calculada es proporcionada dentro de una variación de 5% al administrar directamente el volumen completo de la solución de fármaco antineoplásico desde el primer contenedor de perfusión y el segundo contenedor complementario a un segundo paciente.
MX2022010782A 2016-02-09 2018-08-08 Sistema de perfusion. MX2022010782A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201621004576 2016-02-09

Publications (1)

Publication Number Publication Date
MX2022010782A true MX2022010782A (es) 2022-09-19

Family

ID=59563072

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009670A MX2018009670A (es) 2016-02-09 2017-02-09 Sistema de perfusion.
MX2022010782A MX2022010782A (es) 2016-02-09 2018-08-08 Sistema de perfusion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018009670A MX2018009670A (es) 2016-02-09 2017-02-09 Sistema de perfusion.

Country Status (17)

Country Link
US (3) US11554207B2 (es)
EP (2) EP3413862B8 (es)
JP (2) JP7059190B2 (es)
KR (1) KR102524115B1 (es)
CN (1) CN109069342A (es)
AU (1) AU2017218801B2 (es)
BR (1) BR112018016287A2 (es)
CA (1) CA3014168C (es)
HK (1) HK1258361A1 (es)
IL (1) IL261038B1 (es)
MX (2) MX2018009670A (es)
PH (1) PH12018501693A1 (es)
PL (1) PL3413862T3 (es)
RU (1) RU2728822C2 (es)
SA (1) SA518392177B1 (es)
WO (1) WO2017138023A1 (es)
ZA (1) ZA201805610B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10098813B2 (en) 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
PL3470045T3 (pl) * 2017-10-10 2021-03-08 Sun Pharmaceutical Industries Ltd Dożylna infuzyjna postać dawkowania dla pemetreksedu

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856081A (en) * 1991-07-08 1999-01-05 The American National Red Cross Computer controlled cryoprotectant perfusion apparatus
US5217860A (en) * 1991-07-08 1993-06-08 The American National Red Cross Method for preserving organs for transplantation by vitrification
DE4336336A1 (de) 1992-11-23 1994-05-26 Lang Volker Kasetteninfusionssystem
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
CN2211286Y (zh) * 1994-09-24 1995-11-01 陈利生 加温灌注抗癌机
JPH09168577A (ja) * 1995-12-20 1997-06-30 Sekisui Chem Co Ltd 癌治療用血液バッグ
US5896989A (en) 1998-02-20 1999-04-27 Bracco Research Usa Flexible medical container packaging
US6771697B1 (en) 1998-06-23 2004-08-03 Pctel, Inc. Spread spectrum handshake for digital subscriber line telecommunications systems
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US7243689B2 (en) 2000-02-11 2007-07-17 Medical Instill Technologies, Inc. Device with needle penetrable and laser resealable portion and related method
NZ522766A (en) 2000-05-15 2005-09-30 Celgene Corp Compositions and methods for the treatment of colorectal cancer with irinotecan and thalidomide to reduce side effects
US7352770B1 (en) 2000-08-04 2008-04-01 Intellon Corporation Media access control protocol with priority and contention-free intervals
US7552088B2 (en) 2000-10-02 2009-06-23 International Business Machines Corporation Personally customizable credit card accounts
US6954505B2 (en) 2001-03-29 2005-10-11 Texas Instruments Incorporated Discrete multitone modulation with reduced peak-to-average ratio using unloaded subchannels
US20030039306A1 (en) 2001-04-06 2003-02-27 Redfern Arthur John Low peak-to-average ratio quiescent mode architecture and signal design method for DMT modems
US20030031240A1 (en) 2001-07-31 2003-02-13 Redfern Arthur J. Downstream only suspend-type Q-Mode
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
CN101001782A (zh) 2002-09-03 2007-07-18 因斯蒂尔医学技术有限公司 密封容器和用于制作和填充该容器的方法
JP2004166847A (ja) * 2002-11-18 2004-06-17 Otsuka Pharmaceut Factory Inc 点滴用調合装置、混合管、薬液容器、混合液容器、点滴用調合システムおよび点滴用の調合方法
EP1581284B1 (en) * 2002-12-23 2008-10-15 Medtronic, Inc. Implantable drug delivery systems
DE102005022428A1 (de) * 2005-05-14 2006-11-16 B. Braun Medizinelektronik Gmbh & Co. Kg Verfahren und Vorrichtung zur Steuerung einer Mehrzahl von Infusionspumpen
US20100111941A1 (en) 2006-09-13 2010-05-06 Steven Deitcher Methods for treating cancer
WO2008148080A2 (en) 2007-05-24 2008-12-04 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin]
JP2009034462A (ja) * 2007-07-31 2009-02-19 Koosei Advance:Kk 膵臓治療用灌流システム
WO2009111294A1 (en) 2008-02-29 2009-09-11 Eagle Pharmaceuticals, Inc. Topotecan ready to use solutions
CN102652843B (zh) * 2009-07-01 2015-09-30 弗雷塞尼斯医疗保健控股公司 药物输送装置和相关系统以及方法
FR2951927A1 (fr) * 2009-11-05 2011-05-06 Centre Nat Rech Scient Dispositif de prelevement de liquide corporel et procede de mise en oeuvre.
FR2951951A1 (fr) * 2009-11-05 2011-05-06 Centre Nat Rech Scient Systeme de perfusion securise et procede de mise en oeuvre
AR085215A1 (es) 2011-02-15 2013-09-18 Sanofi Aventis Deutschland Interfaz de dispensacion para uso con un dispositivo dispensador de farmacos que libera dos o mas agentes farmaceuticos
CA2839443A1 (en) * 2011-06-20 2012-12-27 Renaudia Medical, Llc Distributed medication delivery system and method having autonomous delivery devices
US9233776B2 (en) * 2012-06-07 2016-01-12 Bayer Healthcare Llc Molecular imaging vial transport container and fluid injection system interface
EP2861155A4 (en) 2012-06-13 2016-08-17 Py Inst Llc Dr DEVICE WITH PENETRABLE SEPTUM AND CLOSED NEEDLE
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
CN105579018A (zh) * 2013-07-15 2016-05-11 阿尔卡米亚肿瘤学股份有限公司 预制备用于治疗用途的药物的方法
US10098813B2 (en) 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form

Also Published As

Publication number Publication date
HK1258361A1 (zh) 2019-11-08
CA3014168A1 (en) 2017-08-17
RU2018131914A3 (es) 2020-04-30
CN109069342A (zh) 2018-12-21
JP2019504699A (ja) 2019-02-21
RU2728822C2 (ru) 2020-07-31
JP7059190B2 (ja) 2022-04-25
WO2017138023A1 (en) 2017-08-17
EP3413862A4 (en) 2019-07-17
KR102524115B1 (ko) 2023-04-20
EP3413862A1 (en) 2018-12-19
SA518392177B1 (ar) 2022-08-04
JP2022068326A (ja) 2022-05-09
EP3413862B1 (en) 2023-10-18
AU2017218801B2 (en) 2021-11-25
CA3014168C (en) 2023-07-04
KR20180120171A (ko) 2018-11-05
IL261038A (en) 2018-10-31
NZ745728A (en) 2023-08-25
PH12018501693A1 (en) 2019-05-15
PL3413862T3 (pl) 2024-03-18
MX2018009670A (es) 2019-09-04
AU2017218801A1 (en) 2018-09-13
ZA201805610B (en) 2019-05-29
IL261038B1 (en) 2024-02-01
EP4275673A2 (en) 2023-11-15
EP4275673A3 (en) 2023-12-27
US11253642B2 (en) 2022-02-22
EP3413862B8 (en) 2024-03-13
US20200360598A1 (en) 2020-11-19
US11554207B2 (en) 2023-01-17
US20210100947A1 (en) 2021-04-08
RU2018131914A (ru) 2020-03-11
BR112018016287A2 (pt) 2018-12-18
US20230158226A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
EA201690738A1 (ru) Ингалятор сухого порошка
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
NZ701915A (en) High-concentration monoclonal antibody formulations
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
CA3011103A1 (en) Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
MX2022010782A (es) Sistema de perfusion.
MX2017008000A (es) Sistema de inyeccion de un solo uso.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2017015664A (es) Administracion intravenosa de citrulina durante cirugia.
TN2016000083A1 (en) Methods and tools relating to the administration of contrast medium
TH1801004716A (th) ระบบการกำซาบ(Perfusionsystem)
UA105586U (uk) Спосіб лікування печінкової енцефалопатії
UA71921U (ru) Способ лечения токсической нейроретинопатии алкогольной этиологии
UA99309U (ru) Способ лечения ретробульбарного неврита
MD4458C1 (ro) Utilizarea preparatului Polibiolină în tratamentul bolnavilor cu ciroză hepatică
UA99513U (ru) Способ лечения транзиторной ишемической атаки лакунарного генеза
UA84047U (ru) Способ лечения вторичных нарушений системы гемостаза у больных гемофилией с большими интрамышечными гематомами
MD4231C1 (ro) Remediu medicamentos pe bază de troxerutin şi carbazocrom pentru tratamentul gastropatiilor portale în ciroza hepatică
UA89638U (ru) Способ лечения больных пожилого возраста с синдромом сосудистых умеренных когнитивных нарушений
UA89024U (uk) Спосіб комплексного лікування уретеролітіазу
UA99921U (ru) Способ контролируемой седации у пациентов с состоянием отмены алкоголя в отделении интенсивной терапии
MD4232B1 (en) Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure
NZ600486A (en) Pirfenidone treatment for patients with atypical liver function